Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Metanoia Bio Inc. maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are handled by 2 distinct examiners, though they are both situated within 1 distinct art unit. This concentration in 1 distinct art unit suggests that while the examiners differ, the technological focus of the prosecution remains within a specific regulatory group. The firm must navigate the specific examination standards of this unit through the perspectives of the 2 distinct examiners.
The busiest examiner, COLEMAN, BRENDA LIBBY, is currently assigned 1 busiest examiner pending office action. This 1 busiest examiner pending office action accounts for a portion of the total workload in the portfolio. The presence of 2 distinct examiners within 1 distinct art unit implies that the company is engaging with the same unit's policies across its active matters. Practitioners should focus on the consistency of the 1 distinct art unit while managing the 2 distinct examiners to ensure a cohesive strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561247 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | WEDDINGTON, KEVIN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561199 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18561199 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | COLEMAN, BRENDA LIBBY | 1644 | §112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18561247 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | WEDDINGTON, KEVIN E | 1644 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetanoia Bio Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Brenda Libby Coleman has the most, with 1 of Metanoia Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
